461 related articles for article (PubMed ID: 25644430)
21. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
[TBL] [Abstract][Full Text] [Related]
22. 12-O-tetradecanoylphorbol-13-acetate and EZH2 inhibition: A novel approach for promoting myogenic differentiation in embryonal rhabdomyosarcoma cells.
Marchesi I; Sanna L; Fais M; Fiorentino FP; Giordano A; Bagella L
J Cell Physiol; 2018 Mar; 233(3):2360-2365. PubMed ID: 28722764
[TBL] [Abstract][Full Text] [Related]
23. Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis.
Kowalik MA; Guzzo G; Morandi A; Perra A; Menegon S; Masgras I; Trevisan E; Angioni MM; Fornari F; Quagliata L; Ledda-Columbano GM; Gramantieri L; Terracciano L; Giordano S; Chiarugi P; Rasola A; Columbano A
Oncotarget; 2016 May; 7(22):32375-93. PubMed ID: 27070090
[TBL] [Abstract][Full Text] [Related]
24. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
Bois PR; Izeradjene K; Houghton PJ; Cleveland JL; Houghton JA; Grosveld GC
J Cell Biol; 2005 Sep; 170(6):903-12. PubMed ID: 16157701
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
[TBL] [Abstract][Full Text] [Related]
26. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG.
Liu Z; Zhang X; Lei H; Lam N; Carter S; Yockey O; Xu M; Mendoza A; Hernandez ER; Wei JS; Khan J; Yohe ME; Shern JF; Thiele CJ
Nat Commun; 2020 Feb; 11(1):911. PubMed ID: 32060262
[TBL] [Abstract][Full Text] [Related]
27. SMYD1, the myogenic activator, is a direct target of serum response factor and myogenin.
Li D; Niu Z; Yu W; Qian Y; Wang Q; Li Q; Yi Z; Luo J; Wu X; Wang Y; Schwartz RJ; Liu M
Nucleic Acids Res; 2009 Nov; 37(21):7059-71. PubMed ID: 19783823
[TBL] [Abstract][Full Text] [Related]
28. The muscle-specific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation.
Taulli R; Bersani F; Foglizzo V; Linari A; Vigna E; Ladanyi M; Tuschl T; Ponzetto C
J Clin Invest; 2009 Aug; 119(8):2366-78. PubMed ID: 19620785
[TBL] [Abstract][Full Text] [Related]
29. TRAF6-Mediated SM22α K21 Ubiquitination Promotes G6PD Activation and NADPH Production, Contributing to GSH Homeostasis and VSMC Survival In Vitro and In Vivo.
Dong LH; Li L; Song Y; Duan ZL; Sun SG; Lin YL; Miao SB; Yin YJ; Shu YN; Li H; Chen P; Zhao LL; Han M
Circ Res; 2015 Sep; 117(8):684-94. PubMed ID: 26291555
[TBL] [Abstract][Full Text] [Related]
30. Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas.
Mercer SE; Ewton DZ; Shah S; Naqvi A; Friedman E
Cancer Res; 2006 May; 66(10):5143-50. PubMed ID: 16707437
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma.
Vella S; Pomella S; Leoncini PP; Colletti M; Conti B; Marquez VE; Strillacci A; Roma J; Gallego S; Milano GM; Capogrossi MC; Bertaina A; Ciarapica R; Rota R
Clin Epigenetics; 2015; 7(1):82. PubMed ID: 26251675
[TBL] [Abstract][Full Text] [Related]
32. Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation.
Sun M; Huang F; Yu D; Zhang Y; Xu H; Zhang L; Li L; Dong L; Guo L; Wang S
Cell Death Dis; 2015 Aug; 6(8):e1859. PubMed ID: 26291313
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-206 regulates cell proliferation by targeting G6PD in skeletal muscle.
Jiang A; Dong C; Li B; Zhang Z; Chen Y; Ning C; Wu W; Liu H
FASEB J; 2019 Dec; 33(12):14083-14094. PubMed ID: 31675481
[TBL] [Abstract][Full Text] [Related]
34. Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
Seitz G; Warmann SW; Vokuhl CO; Heitmann H; Treuner C; Leuschner I; Fuchs J
Pediatr Surg Int; 2007 May; 23(5):431-9. PubMed ID: 17211591
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
[TBL] [Abstract][Full Text] [Related]
36. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members.
Megiorni F; Cialfi S; McDowell HP; Felsani A; Camero S; Guffanti A; Pizer B; Clerico A; De Grazia A; Pizzuti A; Moles A; Dominici C
BMC Cancer; 2014 Nov; 14():880. PubMed ID: 25427715
[TBL] [Abstract][Full Text] [Related]
37. Progression and Differentiation of Alveolar Rhabdomyosarcoma Is Regulated by PAX7 Transcription Factor-Significance of Tumor Subclones.
Skrzypek K; Adamek G; Kot M; Badyra B; Majka M
Cells; 2021 Jul; 10(8):. PubMed ID: 34440639
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of microRNAs miR-1, -206 and -29 stabilizes PAX3 and CCND2 expression in rhabdomyosarcoma.
Li L; Sarver AL; Alamgir S; Subramanian S
Lab Invest; 2012 Apr; 92(4):571-83. PubMed ID: 22330340
[TBL] [Abstract][Full Text] [Related]
39. Subcellular localization of the steroid receptor coactivators (SRCs) and MEF2 in muscle and rhabdomyosarcoma cells.
Chen SL; Wang SC; Hosking B; Muscat GE
Mol Endocrinol; 2001 May; 15(5):783-96. PubMed ID: 11328858
[TBL] [Abstract][Full Text] [Related]
40. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
